Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9299341 | 0.78 | CTSD (0.33) | — | |
| SCHEMBL18605788 | 0.76 | CYP3A4 (0.44) | CYP3A4TDP1DRD1ESR1ESR2 | |
| Bromide SCHEMBL4318068 | 0.75 | CYP3A4 (0.43) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL2993565 | 0.74 | CYP3A4 (0.41) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL3408265 | 0.74 | CYP3A4 (0.41) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL1304633 | 0.72 | CYP3A4 (0.40) | CYP3A4TDP1DRD1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL16057091 | 0.71 | — | — | |
| SCHEMBL331307 | 0.68 | TDP1 (0.92) | CYP3A4TDP1DRD1ESR1ESR2 | |
| Phosphine SCHEMBL27888053 | 0.68 | TDP1 (0.92) | CYP3A4TDP1DRD1ESR1ESR2 | |
| Phosphine SCHEMBL480827 | 0.68 | TDP1 (0.92) | CYP3A4TDP1DRD1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230086985-A1 | POLYMERIC COMPOUNDS INCLUDING AN ACCEPTOR DYE AND DONOR LUMINOPHORE | UNITED STATES DEPARTMENT OF ENERGY | 2023-03-23 | — | — | US | claimed |
| EP-4061887-A2 | POLYMERIC COMPOUNDS INCLUDING AN ACCEPTOR DYE AND DONOR LUMINOPHORE | North Carolina State University (US) | 2022-09-28 | — | — | EP | claimed |
| WO-2021118782-A2 | POLYMERIC COMPOUNDS INCLUDING AN ACCEPTOR DYE AND DONOR LUMINOPHORE | NORTH CAROLINA STATE UNIVERSITY (US) | 2021-06-17 | — | — | WO | claimed |
| US-20200385583-A1 | POLYMERIC FLUOROPHORES, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF PREPARING AND USING THE SAME | UNITED STATES DEPARTMENT OF ENERGY | 2020-12-10 | — | — | US | claimed |
| EP-3728137-A1 | POLYMERIC FLUOROPHORES, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF PREPARING AND USING THE SAME | North Carolina State University (US) | 2020-10-28 | — | — | EP | claimed |
| EP-3464585-B1 | AZLACTONE FUNCTIONALIZED SUBSTRATES FOR CONJUGATION OF BIOMOLECULES | BOSCH GMBH ROBERT (DE) | 2020-03-11 | — | — | EP | claimed |
| EP-3464585-A1 | AZLACTONE FUNCTIONALIZED SUBSTRATES FOR CONJUGATION OF BIOMOLECULES | Robert Bosch GmbH (DE) | 2019-04-10 | — | — | EP | claimed |
| WO-2017207298-A1 | AZLACTONE FUNCTIONALIZED SUBSTRATES FOR CONJUGATION OF BIOMOLECULES | ROBERT BOSCH GMBH (DE) | 2017-12-07 | — | — | WO | claimed |
| US-20170342211-A1 | AZLACTONE FUNCTIONALIZED SUBSTRATES FOR CONJUGATION OF BIOMOLECULES | ROBERT BOSCH GMBH (DE) | 2017-11-30 | — | — | US | claimed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-12454530-B2 | Amido cyclohexane acid derivatives as LPA receptor inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-28 | — | — | US | disclosed |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250230140-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-07-17 | — | — | US | disclosed |
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-06-12 | — | — | US | disclosed |
| US-20130196971-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| WO-2013041106-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS 11CO FOR CARBONYLATION REACTIONS IN THE PREPARATION OF RADIOPHARMACEUTICALS FOR PET IMAGING | AARHUS UNIVERSITET (DK) | 2013-03-28 | — | — | WO | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| WO-2012079583-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS CO FOR CARBONYLATION REACTIONS | AARHUS UNIVERSITET (DK) | 2012-06-21 | — | — | WO | disclosed |
| EP-2215049-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009058298-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454530-B2 | Amido cyclohexane acid derivatives as LPA receptor inhibitors | LPAR1, LPAR2, LPAR3 | CYP3A4 4682/4885TDP1 3085/4885DRD1 4174/4885 |
| US-20230086985-A1 | POLYMERIC COMPOUNDS INCLUDING AN ACCEPTOR DYE AND DONOR LUMINOPHORE | HLCS, ALG1, ACR | CYP3A4 1491/4885TDP1 2131/4885DRD1 593/4885 |
| US-20130196971-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | CYP3A4 224/4885TDP1 2532/4885DRD1 4452/4885 |
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | CYP3A4 4198/4885TDP1 3360/4885DRD1 4207/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | CYP3A4 297/4885TDP1 4265/4885DRD1 4813/4885 |
| US-20200385583-A1 | POLYMERIC FLUOROPHORES, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF PREPARING AND USING THE SAME | CLTB, PAICS, HLCS | CYP3A4 2891/4885TDP1 2927/4885DRD1 1707/4885 |
| US-20250230140-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | LPAR3, LPAR2, LPAR1 | CYP3A4 3615/4885TDP1 3298/4885DRD1 3630/4885 |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | CYP3A4 4268/4885TDP1 4039/4885DRD1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.